Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Washington University School of Medicine
Henry Ford Health System
University of Nebraska
University of Maryland, Baltimore
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The Christie NHS Foundation Trust
University of Cincinnati
National Health Research Institutes, Taiwan
Masonic Cancer Center, University of Minnesota
Johannes Gutenberg University Mainz
ASLAN Pharmaceuticals
Jules Bordet Institute
University College, London
University of California, San Francisco
University of Colorado, Denver
University of California, San Francisco